Allist(SH:688578)2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥217,331,089.34, a decrease of 40.68% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥27,167,799.85, down 87.26% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥14,786,510.81, a decline of 92.45% compared to the previous year[4] - The basic earnings per share for Q3 2022 was ¥0.06, down 87.15% from the previous year[4] - The weighted average return on equity for Q3 2022 was 0.90%, a decrease of 6.21 percentage points year-on-year[4] - The net profit for Q3 2022 was CNY 53,932,347.03, a decrease from CNY 134,907,629.99 in Q3 2021, representing a decline of approximately 60%[19] - The total comprehensive income for Q3 2022 was CNY 58,289,725.34, compared to CNY 134,907,629.99 in the same period last year, indicating a significant drop[20] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.12, down from CNY 0.30 in Q3 2021, reflecting a 60% decrease[20] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥3,209,823,390.04, representing a 2.54% increase from the end of the previous year[4] - Total assets as of Q3 2022 were ¥3,209,823,390.04, compared to ¥3,130,259,503.93 at the end of Q3 2021, representing an increase of about 2.5%[17] - Total liabilities for Q3 2022 were ¥122,334,396.04, down from ¥156,994,583.02 in Q3 2021, indicating a decrease of approximately 22.0%[17] - Current liabilities decreased to ¥121,650,328.31 in Q3 2022 from ¥156,118,414.67 in Q3 2021, a reduction of approximately 22.0%[17] - Non-current assets totaled ¥1,051,644,368.18 in Q3 2022, compared to ¥755,591,182.03 in Q3 2021, reflecting an increase of about 39.2%[17] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥33,891,027.22, a decrease of 62.20% compared to the previous year[4] - The net cash flow from operating activities for Q3 2022 was CNY 33,891,027.22, down from CNY 89,654,449.26 in Q3 2021, showing a decline of approximately 62%[22] - Cash inflows from operating activities totaled CNY 502,161,946.44 in the first nine months of 2022, an increase from CNY 468,037,886.54 in the same period of 2021[22] - The net cash flow from investment activities for Q3 2022 was CNY 344,523,296.53, down from CNY 517,607,389.65 in Q3 2021, indicating a decline of approximately 33%[22] - The net cash flow from financing activities for Q3 2022 was -CNY 4,794,898.20, compared to -CNY 8,887,174.60 in Q3 2021, showing an improvement[23] - The cash and cash equivalents at the end of Q3 2022 amounted to CNY 1,003,115,669.03, an increase from CNY 965,234,645.72 at the end of Q3 2021[23] Research and Development - Research and development expenses for Q3 2022 totaled ¥48,358,426.09, a decrease of 31.63% year-on-year[4] - The ratio of R&D expenses to operating revenue for Q3 2022 was 22.25%, an increase of 2.94 percentage points compared to the same period last year[4] - Research and development expenses for Q3 2022 amounted to ¥137,289,093.00, a decrease from ¥163,359,434.53 in Q3 2021, reflecting a reduction of approximately 15.9%[18] - The company continues to expand its clinical research and commercialization processes for Furmetin, demonstrating its commitment to innovation[13] - The company is focused on enhancing its market presence and product offerings through ongoing research and development efforts[13] Product Development and Market Presence - The company achieved a revenue of 518 million RMB for the first nine months of 2022, showing significant growth despite external macroeconomic challenges[13] - The sales revenue of the drug Furmetin increased after its inclusion in the national medical insurance directory at the end of 2021, with further positive impact from its approval for first-line treatment in June 2022[13] - The company is actively preparing for negotiations regarding the inclusion of Furmetin's first-line treatment in the national medical insurance directory[13] - Furmetin received approval for a Phase II clinical trial for non-small cell lung cancer with specific mutations in August 2022, indicating ongoing clinical research and expansion of its indications[13] - The company was recognized as one of the "Top 100 Hard-Core Enterprises in Shanghai" in 2022, highlighting its innovative capabilities[13] - Furmetin was awarded as one of the "Top Ten New Drugs (Domestic)" at the 14th Health China Forum, emphasizing its quality and efficacy[13]